External validation of DEPs and biomarker panels should be performed on HD patients using public HD datasets, and biomarker analysis should be performed on other NDs (AD, PD and ALS) to assess the specificity and sensitivity of CAP1 and CAPZB. The gene discussed is CAP1; the disease is amyotrophic lateral sclerosis.